

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 51320-AB/JPW/AJD/BWSL 09/852,238
Applicant(s)

G. P. Allaway et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date Art Unit May 9, 2001 1648

U.S. PATENT DOCUMENTS

Examiner Initials	Exh. No.		Do	cu n	ient	Numi	ber		Date	Name	Class	Subclass	Filing Date If Appropriate
BUG	1	6	1	0	7	0	1	9	08/22/00	Allaway et al.			
BUC	2	6	3	4	4	5	4	5	02/05/02	Allaway et al.	_		
13000	3	6	5	4	8	6	3	6	04/15/03	Dragic et al.			
BUC;	4					laim 3, 9 3		•		Allaway et al.			06/25/01
BUC	5					laim 3, 3 1				Dragic et al.			12/19/02
BUC	6	08	6	2	7	6	8	4		Allaway et al.			04/02/96
BUCC		60	0	1	4	5	3	2		Allaway et al.			04/02/96
HUC.	7	08	6	6	3	6	1	6		Allaway et al.		-	06/14/96
BUC		60	0	1	9	7	1	5		Allaway et al.			06/14/96
BUC	8	08	6	7	3	6	8	2		Allaway et al.			06/25/96
B(((,	9	08	6	6	5	0	9	0		Allaway et al.			06/14/96

FOREIGN PATENT DOCUMENTS

			Do	· 11 PH-4	ent N	Ju mi	.ar		Date	C		0.1.1	Trans	lation
			<i>D</i> 00	. W 1111	, 14C 1	1 (4)))	JC1		Date	Country	Class	Subclass	Yes	No
Baci	26	9	6	4	1	0	2	0	10/27/97	PCT				
1	27	9	7	2	6	0	0	9	07/24/97	PCT		· · · · · · · · · · · · · · · · · · ·		
	28	9	7	3	7	0	0	5	10/27/97	PCT				
	29	9	8	5	6	4	2	1	12/17/98	PCT		·		
	30	0	0	3	5	4	0	9	06/2/2/00	PCT	1.			
	31	0	1	6	4	7	1	0	09/07/01	PCT		····-		
	32	.0	2	2	2	0	7	7	03/21/02	PCT				
Ą	33	02	0	6	8	6	0	8	09/06/02	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER / DATE CONSIDERED /

Buggent

Of 65 Hor

^{*}EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Form PTO-PARADE

U.S. Department of Commerce Patent and Trademark Office

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Atty. Docket No. 51320-AB/JPW/AJD/BWSL

Serial No. 09/852,238

Applicant(s)

G. P. Allaway et al.

Filing Date May 9, 2001 Art Unit 1648

U.S. PATENT DOCUMENTS

Examiner Initials	Exh. No.		Doc	ume	nt N	u mt	ег		Date	Name	Class	Subclass	Filing Date If Appropriate
Blei		60	0	1	9	9	4	1		Allaway et al.			06/14/96
BUC	10	08	8	7	4	5	7	0		Allaway et al.			06/13/97
BUCCI	11	08	8	7	4	6	1	8		Allaway et al.			06/13/97
BUC	12]	Pend 0 9		Cla 2 4,					Allaway et al.			11/28/00
BUC	-	09	2	1	2	7	9	3		Olson et al.			12/16/98
Bie		60	1	1	2	5	3	2	_	Olson et al.			12/16/98
BUC	13	09	4	6	4	9	0	2		Olson et al.			12/16/99
BOI	14	09	5	9	4	9	8	3		Olson et al.			06/15/00
BUC	15	09	6	6	3	2	1	9		Olson et al.			09/15/00
BUCC	16	60	2	6	6	7	3	8		Olson et al.			02/06/01
BU	17	2 (0 0 2	$\bar{2}/\bar{0}$	1 4	6 4	1 5	5	10/10/02	Olson et al.			
1300	18	60	2	8	2	3	8	0		Olson et al.			04/06/01
Bill	19	2 (002	2/0	10	6 3	7 4	ļ	08/08/02	Olson et al.			
BCC	20	10	0	8	1	1	2	8		Olson et al.			02/22/02
BUCC		60	3	5	8	8	8	6		Olson et al.			02/22/02
BCEC	21	2 (0 0 3	3/0	0 4	4 4	1 1		03/06/03	Olson et al.			
BOC.	22		0 0 3						05/15/03	Dragic et al.			
BUC	23	2 (0 0 3	3/0	2 2	8 3	0 6		12/11/03	Olson et al.			
BUC	24		end							Olson et al.			01/23/04
BULL	25		end 09					·		Allaway et al.			12/13/99

FOREIGN PATENT DOCUMENTS

			Doc	uma	ne N				Data	C4	GI.		Trai	slation
			DUC	u me	11 14	um	ię i		Date	Country	Class	Subclass	Yes	No
BCC	34	02	0	8	3	1	7	2	10/24/02	PCT				
13(0)	35	03	0	7	2	7	6	6	09/04/03	PCT			ļ -L	

EXAMINER

DATE CONSIDERED 03/05/2004

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 1 of 6 Form PTO-1449 Serial No. Atty. Docket No. **U.S.** Department of Commerce 51320-AB/JPW/SHS 09/852,238 Patent and Trademark Office Applicants Graham P. Allaway et al. FORMATION DISCLOSURE CITATION (Use several sheets if necessary) Filing Date Group May 9, 2001 U.S. PATENT DOCUMENTS Examiner **Document Number** Class Date Name Subclass Filing Date Initial if Appropriate BULLIUS 5 8/5/94 Chuntharapai, et al BOL 5 US 5 0 4 0 0 3 4/2/96 H. Li et al. BOCI US 19 6/4/91 Murrer et al. IUS 6/30/92 Maddon, et al. FOREIGN PATENT DOCUMENTS **Document Number** Date Country Class Subclass Translation Yes No COG WOD 12/18/97 OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Alkhatib, Ghalb, et al., (1996) "CC CKR5: A RANTES, MIP-1α, MIP-1β Receptor as a BOL Fusion Cofactor for Macrophage-Tropic HIV-1" Science 272:1955-1958; Arenzana-Selsdedos, Fernando, et al., (1996) "HIV blocked by chemokine antagonist" Nature 383:400; Bleul, Conrad, C., et al., (1996) "The lymphocyte chemoattractant SDF-1 is a ligand for Blok LESTR/fusion and blocks HIV-1 entry" Nature 382:829-832; Brenner, T.J., et al. (1991) "Relation between HIV-1 syncytium inhibition antibodies and clinical outcome in children" The Lancet 337:1001-1005; Choe, Hyeryun, et al., (1996) "The β-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates" Cell 85:1135-1148; Cocchi, Florenza, et al., (1995) "Identification Of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8⁺ T Cells" Science 270: 1811-1815; De Clercq, et al.,(1994) "Highly potent and selective inhibition of human immunodeficiency Bal virus by the bicyclam derivative JM3100" Antimicrobial Agents and Chemotherapy 38(4):668-674: De Clercq, E., (1995) "Antiviral therapy for human immunodeficiency virus infections" Clinical Microbiology Reviews 8(2):200-239; Doranz, et al., (1996) "A dual-tropic primary HIV-1 isolate that uses fusin and the βchemokine receptors CKR-5, CKR-3, and CKR-2b as fusin cofactors" Cell 85:1149-1158;

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE CONSIDERED

EXAMINER_

Bachink

Sheet 2 of 6 Form PTO-1449 Atty. Docket No. Serial No. **U.S. Department of Commerce** 51320-AB/JPW/SHS 09/852,238 Patent and Trademark Office Applicants Graham P. Allaway et al. **FORMATION DISCLOSURE CITATION** (Use several sheets if necessary) Filing Date Group May 9, 2001 U.S. PATENT DOCUMENTS Example 1- 105 **Document Number** Date Class Name Subclass Filing Date Initial if Appropriate FOREIGN PATENT DOCUMENTS **Document Number** Date Country Class Subclass Translation Yes No OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Dragic, T. et al., (1996) "HIV-1 entry into CD4+ cells is mediated by the chemokine receptor BU CC-CKR-5" Nature 381:667-673; Gong, Jiang-Hong, et al., (1995) "Antagonists Of Monocyte Chemoattractant Protein 1 BUCC Identified By Modification Of Functionally Critical NH2-terminal Residues" J. Exp. Med. 181:631-640; BLOC Gong, Jiang-Hong, et al., (1996) "RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors" The Journal of Biological Chemistry 371:10521-10527; Hattori, T., et al., (1989) "Involvement of tryptase-related cellular protease(s) in human immunodeficiency virus type 1 infection" FEB 248:48-52; Jones, Simon, A., et al., (1997) "Chemokine Antagonists That Discriminate between Interleukin-8 Receptors" The Journal of Biological Chemistry 272:16166-16169; BUC Klotman, et al., (1995) "Transgenic models of HIV-1" AIDS 9(4)313-324; Litwin, et al., (1996) "Human immunodeficiency virus type 1 membrane fusin mediated by a BUC laboratory-adapted strain and a primary isolate analyzed by resonance energy transfer" Journal of Virology 70(9):6437-6441; McKnight, Aine, et al., (1997) "Inhibition of Human Immunodeficiency Virus Fusion by a BUC Monoclonal Antibody to a Coreceptor (CXCR4) Is both Cell Type and Virus Strain Dependent" Journal of Virology 71(2): 1692-1696; Moser, Bernhard, et al., (1993) "Interleukin-8 Antagonists Generated by N-terminal BU Modification" The Journal of Biological Chemistry 268:7125-7128; EXAMINER DATE CONSIDERED 09/05 4004 Boiggin L *EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with

next communication to applicant.

Sheet 3 of 6

Form PTO	-144	9					-	at of Commerce lemark Office	Atty. Doc 51320-A	ket No. B/JPW/SHS	Serial N 09/852	
- T	NEO.	ΦM.	a Ti	n I				CITATION	Applicant Graham	s P. Allaway et a	al.	
OPE	6						s if necess		Filing Dat May 9,	te	Group	
JAN 28 20	02 E						U.S. PA	TENT DOCUME	NTS			
Examiner Mirig	N C	Docu	ımen	ıt N	vumb	er	Date	Name	Class	Subclass	Filing D	
0 10	\perp									ļ <u> </u>		·
		\coprod		\downarrow	\bot							
	\bot	\sqcup	_	\downarrow	\dashv						ļ	
	l											
								PATENT DOCUM		Т	1	
	D	ocui	men	ıt ľ	Num	ıber	Date	Country	Class	Subclass		nslation
	+	1 1	Т		Т	r			<u> </u>	Yes	No	
	+	\vdash	+	+	\dashv	+-			-			
	+	╂╌┼		+	+	+			_		-	
	+	H	+	+	_	+-			 		1	
		Γ	THE	ER	DO	LUME	NTS (Inclu	lding Author, Title, Da	te. Pertinen	t Pages, Etc.)		
B60 (:		erlir	ı, Es	stel	lle, e	et al.,	(1996) "Tl	ne CXC chemokine ine-adapted HIV-1	SDF-1 is the	he ligand for	LESTR	fusion
BRC	Ra	port,	, Cai	rol	J.,	et al.		lew members of the			ne family	y" Journal
BOL	Si	nmo	ns, (Gra	ahar	n, et	al., (1997)	"Potent Inhibition o Antagonist" Science			lacropha	iges and
BUC		•		-	•	,	CD4 change 596-3604;	es conformation upo	on ligand bi	inding" <i>The J</i>	ournal c	of
RUC						•		'CD4-dependent, an "Nature 384:184-1	•	sitive interact	tions bet	tween
BUC	`				-		et al., (199 Biology 59:	6) "Selectivity and a 53-60;	antagonism	of chemokin	e recept	ors"
BU!						-	•	duced interaction of Nature 384:179-183	_	IIV-1 gp120 g	glycopro	teins with
310°		-				•	•	Levels and Expression or J. Exp. Med. 18			h Infecta	ability by
BOCI				-			•	ure/Activity Analys is," <i>The Journal of</i> .		-		
EXAMINER	K	Sou, E	Ĵil	n	L;		DATE CON	SIDERED 09/05/	1004			
	nroug		tati	on	if	not i		ether or not citat: nce and not conside				

Sheet 4 of 6

													nect_4 or	<u> </u>		
Form P									-	nt of Commerce demark Office	Atty. Doc 51320-A	cket No. AB/JPW/SHS	Serial N 5 09/852			
. ا	-12	FOI	RM	[A]	ΓΙΟ	N I	DIS	SCI	LOSURE (CITATION	Applicant Graham	ts P. Allaway et a	ıl.			
OLAF	JC.	2							s if necess		Filing Da May 9,		Group			
JAN 2 8	3000	Ĭ							U.S. PA	TENT DOCUMEN	ITS					
Examiner Intellar	TRADE		Doc	:um	ent l	Nun	nber	<u></u>	Date	Name	Class	Subclass	Filing D			
				L												
	<u> </u>						L									
								<u>F</u>	OREIGN	PATENT DOCUM	ENTS					
		De	ocu	ıme	ent l	Nu	mb	er	Date	Country	Class	Subclass	Tran	nslation		
					 -						 	<u> </u>	Yes	No		
		Щ														
	<u> </u>	Щ			ļ		 									
		dash	\vdash	\vdash	Щ						 	 	1			
	<u></u>	<u></u>				Щ					<u> </u>	1				
		137.1								ding Author, Title, Dat Chemokine Receptor				la.		
BUC		Doı	mai	ins	for	HI	V-1	gp		ng and a Single Doma				<u>.</u>		
BUC	jέ	gpl	20	Bir	ndir	ng,	and	i CC		nhibition of Human I						
					414											
BOC	~ (Мо	dul	les i	for i	in v	/ivo	St		cient Mice Xenograft uman Immunobiolog 191;						
BOC	1	Poi	gna	ard,	P. 6	et a	l,.,	199	99, Neutrali	izing Antibodies hav			e Contro	ol of		
BC C		pro	lon	ged	l A I	IDS	-fre	ee s		erozygosity for a dele d slower CD4 T=cell						
BOC										ted Frequency of CC		eterozygotes	among l	ong-term		
EXAMINER	Bo	(10)	70	civ	6	1			DATE CONS	IDERED 09/05	Loap					
*EXAMINER Draw line	thr	ough	ı ci	itat	tion	ı if	no	ons t i	idered, wh n conforma	ether or not citation not consider	on is in c red. Inclu	conformance winde copy of the	ith MPEP nis form	609: with		

Sheet 5 of 6 Atty. Docket No. Serial No. 51320-AB/JPW/SHS 09/852,238

					1	Pate	nt and Tra	demark Office	51320-A	B/JPW/SHS	S 09/852	.,238
OIPE	nteo)	RM.	ΑТ	IOI				CITATION	Applicant Grahan	s n P. Allaway	et al.	0
JAN 2 8 20	~~	•					ets if necess		Filing Dad May 9,		Group	
PEN O THANK	JART						U.S. PA	TENT DOCUME	NTS			
Examiner Initial		Doc	ume	nt N	um	ber	Date	Name	Class	Subclass	Filing D	
	_		_	_	_	_						
 	+	\vdash			\dashv	_				 	 	
	+		寸	_	7		- 					
<u> </u>		L			•		FOREIGN	PATENT DOCUM	MENTS			
	D	ocu	me	nt N	Vur	nbei	Date	Country	Class	Subclass	Tra	nslation
											Yes	No
	工				į							
			_			_						
	-		_	_	\dashv	_	-				-	
										<u> </u>	<u> </u>	
	_							ling Author, Title,				
BCCC								munodeficiency viru Chemistry and Che			iokine re	ceptors: a
BC C	Ch	emo	kin	ies:	Inc	lepe	idence from	oreceptor Activity of G Protein Signaling				· down
							234:340-34		1	mar Dalas In V	/inal End	
BCC.		_			•			Receptors as HIV- Immunol. 17:657-70		rs: Roles III V	virai Eili	<u>. </u>
130 (_	´ (H)	(V)	1 a	nd I	/IH	/-2 F		it and Selective Inhil By a Class of Bicycl 286-5290;				
BOL	Do CX	ranz CR	z et 4 P	al., reve	(19 ents	997). s Its	, A Small M Use As An	Iolecule Inhibitor Di HIV-1 Coreceptor,	rected Aga I.Exp.Med.	inst the Chen 186 (8):1395	nokine P -1400;	leceptor
BU C								Pathogenesis: The Rounnology Today 17:2		oncytotoxic A	Anti-HI`	V
130 C		lleri (12)	-				, Enzyme-I	mmunoassay: A Rev	iew, J. Cli	n. Chem .Clir	ı.Bioche	<i>m</i> .
EXAMINER		در ر					DATE CON	SIDERED 09/0	4/2006			

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Department of Commerce

Form PTO-1449

*EXAMINER: Initiad if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

09/01/204

DATE CONSIDERED

EXAMINER

				1
Form PT)-1449 1	3	200°	100 × 100
, ,	^			15

DIPE

U.S. Department of Commerce Patent and Trademark Office

Atty. Docket No. 51320-AB/JPW/SHS 09/852,238

	E S	20 0	DN/A	T	TON		TÇ	CI	OSTIDE	CITATION	Applicant Graham	s P. Allaway et a	ıl.	
	1141	,							s if necess		Filing Dat May 9,	e	Gr up	
									U.S. PA	TENT DOCUMEN	TS			
Examiner Initial			Docu	me	nt N	uml	er		Date	Name	Class	Subclass	Filing Dail	
BRC,	US	5	4 4	1	0	5	2	1	8/5/94	A. Chuntharapai, et al.	_			
-	US	5	5		4	5	0	3	4/2/96	H. Li et al.		_		
	US	5	0\2		1 4	C	,	9	6/4/91	Murrer et al.	٠٠٠٠ سين			
• 1	US	1	1 2		6 4	_	;	3	6/30/92	Maddon et al.		_		
			<u>- 1</u>	<u> </u>				F	OREIGN	PATENT DOCUM	ENTS	<u> </u>		
·		D	ocun	ne)	nt N	un	ıbe		Date	Country	Class	Subclass	Tran	slation
													Yes	No
		-	П	Т	X	Т						*	1	
				+	1	4	1						1	
· · · · · · · · · · · · · · · · · · ·		\vdash		+	\dashv	\uparrow	\exists						1	
		-	\vdash	\dashv	-+	+	A				 -		+	
		<u> </u>	ᄔ				_}	/-	L	ding Author, Title, Date	1			
1310 ()		Fu Ar	sion (Co 1a-	fact	or 1	or	M	adrophage	CC CKR5; A RANTE -Tropic HIV-1" Scient et al., (1996) "HIV blo	nce 272:1	955-1958;	-	· · · · · · · · · · · · · · · · · · ·
			•				-			The lymphocyte cher entry Nature 382:82		nt SDF-1 is a	a ligand	for
										lation between HIV-1 e Lancet 337:1001-10		m inhibition	antibodi	es and
										he β-Chemokine Recentes" Cell 85:1135-11		R3 and CCR:	5 Facilita	ate
		Co	cchi,	Fl	orei	ıza	et	al	., (1995) "	Identification Of RAN Produced by CD8 ⁺ T	NTES, MI			
			us by							potent and selective in JM3100" <i>Antimicrobi</i>				
				•		•		•		therapy for human im (2):200-239;	munodefi	siency virus	infectior	ıs"
V		Do	ranz,	et	al.,	(19	96	5) '	'A dual-tro	pic primary HIV-1 is R-3, and CKR-2b as			•	158;
EXAMINE	R		cioq						DATE CON	CERRER	5/1005			

*EXAMINER: Initial of citation considered, whether or not citation is in conformance with MPEP 609: Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		0	P P	E	_						S	heet 2 of	3
Form PTC	- 1		13	200	445				nt of Commerce lemark Office	Atty. Doc 51320-A	ket No. A/JPW/SHS	Serial N 09/852	
)	Ħ				٢	i DIS	CL	OSURE (CITATION	Applicant Graham	s P. Allaway et a	d	
	~							s if necess		Filing Da May 9,		Group	
								U.S. PA	TENT DOCUME	NTS			
Examiner Initial		Doc	cume	ent l	Nun	ıber		Date	Name	Class	Subclass	Filing D	
	_			_									
•		_	L	L								<u> </u>	
	_											ļ	····
				<u> </u>			L	<u> </u>			<u> </u>		
							F	OREIGN	PATENT DOCUM	1ENTS			
	a	ocu	ıme	nt	Nu	mb	er	Date	Country	Class	Subclass	Tra	nslation
					_							Yes	No
		<u> </u>											
		Ļ	_				<u> </u>	!				· .	
		<u> </u>					_						
								Ĺ <u>.</u>					
									ding Author, Title, Da				
BUC		_	-\		-	•		5) "HIV-1 e 31:667-673	ntry into CD4+ cell	s is mediat	ed by the che	mokine	receptor
. /	Ide	nti		Ву	W				"Antagonists Of Monctionally Critical N				
									"RANTES and MCI nal of Biological Ch				
	Ha	ttor	i, T	`., e	t al.	., (1	38	9) "Involve	ement of tryptase-related fection FEB 248:4	lated cellul			an
									Chemokine Antagon				
	KI	otm	an,	et a	al.,	(19	95)	"Transgen	ic models of HIV-1	" <i>AIDS</i> 9(4	1)313-324;		
	lab	ога	tory	y-ac	dapt	ted :	stra		nunodeficiency viru imary isolate analy:	· -			•
	M	ono	clor	nal .	Ant	ibo	dy	to a Corece	nhibition of Human eptor (CXCR4) Is b 11(2): 1692-1696;				n by a
4			•						nterleukin-8 Antago logical Chemistry 2	•	•	rminal	
EXAMINER			γυ		1				SIDERED / 5 /				
	throug	jh ¢	tat	tior	n if	e no	t i		ether or not citat nce and not conside				

		Į.	ا غ	AUB	1 3		186	}			s	heet 3 of	3
Form PT	O-14	49	R.	היילה	ושרונ	U.S	S. I ten	Department	t of Commerce emark Office	Atty. D c. 51320-A	ket No. A/JPW/SHS	Serial No S 09/852	
	INFO)RM	(A)	rio)N]	DIS	CI	LOSURE C	ITATION	Applicant Graham l	s P. Allaway et a	ıl.	
								ts if necessa		Filing Dat May 9,		Group	
								U.S. PAT	FENT DOCUME	NTS			
Examiner Initial		Do	cum	ent	Nun	nber		Date	Name	Class	Subclass	Filing Da	
•									_				
		1			Τ								
					-		F	OREIGN I	PATENT DOCU	MENTS			
]	Doci	ume	ent	Nu	mb	er	Date	Country	Class	Subclass	Trar	slation
			1	Τ	_	T	Γ					Yes	No
		-	\vdash		-	_	-						· · · · · · · · · · · · · · · · · · ·
	-	+	1	\vdash	1-	\vdash						1	
	_	\top				T					<u> </u>		
			OTI	HER	R DO	ocu	MI	ENTS (Includ	ling Author, Title, D	ate, Pertinen	t Pages, Etc.)		
BU (berl	in,	Ęste	elle	, et	al.,	(1996) "Th	e CXC chemokine ne-adapted HIV-1	SDF-1 is t	he ligand for	LESTR/	fusion
*				$\overline{}$	$\overline{}$							Comile	ell Tossen

Raport, Carol, J., et al., (1996) "New members of the chemokine receptor gene family" Journal of Leukocyte Biology 59:18-23; Simmons, Graham, et al., (1997) "Potent Inhibition of HIV-1 Infectivity in Macrophages and Lymphocytes by a Novel CCR5 Antagonist" Science 276:276-279; Szabo, et al., (1992) "CD4 changes conformation upon ligand binding" The Journal of Immunology 149(11):3596\3604; Trkola, Alexandra, et al., (1996) "CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR 5" Nature 384:184-187; Wells, Timothy, N.C., et al., (1996) "Selectivity and antagonism of chemokine receptors" Journal of Leukocyte Biology 59\$53-60; Wu, Lijun, et al., (1996) "CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5," Nature 384:179-183; Wu, Lijun, et al., (1997) "CCR5 Levels and Expression Pattern Correlate with Infectability by Macrophage-tropic HIV-1, In Vitro" J. Exp. Med. 185:1681-1691; Zhang, Y,J., et al., (1994) "Structure/Activity Analysis of Human Monocyte Chemoattractant Protein-1 (MCP-1) by Mutagenesis," The Journal of Biological Chemistry 269:15918-15924;

EXAMINER Scient Date considered 09/05/2004

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609: Draw line through ditation if not in conformance and not considered. Include copy of this form with next communication to applicant.